OverviewChartNewsTraderScreen

Soc. Generale Bonus Zert AMD 27.0.../  DE000SU9Y6G1  /

EUWAX
5/15/2024  8:30:05 AM Chg.+2.15 Bid6:15:57 PM Ask6:15:57 PM Underlying Strike price Expiration date Option type
148.65EUR +1.47% 150.70
Bid Size: 5,000		 150.86
Ask Size: 5,000		 Advanced Micro Devic... - USD 6/27/2025 Call
GlobeNewswire 5/14 UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates
GlobeNewswire 5/14 AMD Announces Upcoming Events for the Financial Community
GlobeNewswire 5/14 Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facilit...
GlobeNewswire 5/14 Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire 5/13 Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5...
GlobeNewswire 5/13 AMD Remains the Partner of Choice for World’s Fastest and Most Efficient High Performance Computing ...
GlobeNewswire 5/9 Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire 5/9 Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlight...
GlobeNewswire 5/9 4DMT Reports First Quarter 2024 Financial Results and Operational Highlights
GlobeNewswire 5/8 Alkeus Pharmaceuticals Announces Positive Interim Results Demonstrating No Signs of Disease Progress...
GlobeNewswire 5/8 Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegener...
GlobeNewswire 5/8 AMD Receives IEEE 2024 Corporate Innovation Award for Leadership in Chiplet Design for High-Performa...
GlobeNewswire 5/8 Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results
GlobeNewswire 5/8 EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporat...
GlobeNewswire 5/7 Ocular Therapeutix™ Reports First Quarter 2024 Results
GlobeNewswire 5/7 Optiver Chooses AMD Enterprise Portfolio to Power its Data Center Modernization, Enabling New Era of...
GlobeNewswire 5/7 Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
GlobeNewswire 5/7 Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 5/6 Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD
GlobeNewswire 5/6 Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease ...
GlobeNewswire 5/6 Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at th...
GlobeNewswire 5/6 Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences
GlobeNewswire 5/6 EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Prol...
GlobeNewswire 5/3 Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024
GlobeNewswire 5/3 YieldMax™ ETFs Announces Monthly Distributions on CONY (109.51%), MSTY (103.22%), NFLY (67.74%), SQY...